Medical management to optimize donor organ potential: review of the literature.
OBJECTIVE
Over the past two decades, the demand for donor organs continues to outpace the number of organs available for transplantation. Parallel with this has been a change in the demographics of organ donors with an increase in older donors and donors with marginal organs as a proportion of the total organ donor pool. Consequently, efforts have been made to improve the medical care delivered to potential organ donors to improve the conversion rate and graft survival of available organs. The purpose of this literature review is to provide updated recommendations for the contemporary management of organ donors after the neurological determination of death in order to maximize the probability of recipient graft survival.


METHODS
A comprehensive review of the literature obtained through searches of MEDLINE/PubMed, and personal reference files.


RESULTS
Contemporary management of the organ donor after neurological determination of death includes therapies to prevent the detrimental effects of the autonomic storm, the use of invasive hemodynamic monitoring and aggressive respiratory therapy including therapeutic bronchoscopy in marginal heart and lung donors, and the use of hormonal therapy including vasopressin, corticosteroids, triiodothyronine or thyroxine, and insulin for the pituitary failure and inflammation seen in brain dead organ donors. The importance of normalizing donor physiology to optimize all available organs is stressed.


CONCLUSIONS
Aggressive hemodynamic and respiratory management of solid organ donors, coupled with the use of hormonal therapy improves the rate of conversion and graft survival in solid organ recipients.
Kutsogiannis
Demetrios J
DJ
Division of Critical Care Medicine and Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada. dkutsogi@telusplanet.net
Pagliarello
Giuseppe
G
Doig
Christopher
C
Ross
Heather
H
Shemie
Sam D
SD
D001926:Brain Death; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003422:Critical Care; D003643:Death; D006085:Graft Survival; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D019141:Respiratory System Agents / Q000627:therapeutic use; D009927:Tissue and Organ Procurement
D002317:Cardiovascular Agents; D006728:Hormones; D019141:Respiratory System Agents